Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Bearish -65

Novo Nordisk Must Face Shareholder Suit Over CagriSema Weight Loss Trial

🏛️ U.S. District Judge Robert Kirsch ruled that Novo Nordisk must face a shareholder lawsuit alleging fraud over the CagriSema clinical trial.

📉 Novo Nordisk's American depositary receipts dropped 17.8% on December 20, 2024, following the news of the legal ruling and trial results.

⚖️ The judge found that executive Martin Holst Lange intended to defraud investors by falsely implying dosing protocols were consistent with previous trials.

📊 CagriSema achieved a 20.4% weight reduction, missing its 25% target and falling below the 22.5% benchmark set by Eli Lilly's Zepbound.

💊 The trial protocol was altered to let participants control their own dosages, with only 57% receiving the highest dose, raising tolerability concerns.

📄 In a 56-page decision, Judge Kirsch dismissed claims regarding fixed doses and 'unsurpassed' weight loss projections but left surviving fraud claims intact.

👥 The Redefine 1 clinical trial covered approximately 3,400 adults with body mass indexes of at least 30 or specific weight-related conditions.

⚔️ Novo Nordisk sued Eli Lilly on July 21 for allegedly falsely advertising Zepbound and Mounjaro by comparing higher doses to lower doses of Novo's drugs.

🗓️ A federal judge will consider a preliminary injunction request to halt Eli Lilly's nationwide ads at an August 27 hearing in Trenton.

💼 CagriSema combines semaglutide from Wegovy with cagrilintide, mimicking the pancreatic hormone amylin.

Risk Factors
  • ⚠️ Novo Nordisk's stock fell 17.8% immediately after the company revealed it missed its weight loss target and altered trial protocols.
  • ⚠️ The court found that an executive intended to mislead investors about dosing protocols, creating a specific fraud liability for the company.
  • ⚠️ Only 57% of trial participants received the highest dose, raising concerns about treatment tolerability and potential side effects.
  • ⚠️ CagriSema's 20.4% weight loss result fell short of both its internal 25% target and the 22.5% benchmark investors expected from competitors.
  • ⚠️ The judge dismissed claims regarding fixed doses but explicitly noted that projections of 'unsurpassed' weight loss were merely aspirational, limiting positive spin.
  • ⚠️ The company faces a significant shareholder lawsuit alleging fraud over the CagriSema trial results and executive communications.
Full Analysis
A U.S. federal judge in Trenton, New Jersey, ruled on Tuesday that Novo Nordisk must face a shareholder lawsuit alleging fraud regarding its CagriSema weight loss trial. The court found sufficient evidence that Martin Holst Lange, the company's former executive vice president of development and current chief scientific officer, intended to mislead investors by falsely implying that the clinical trial used standard dosing protocols identical to previous studies. The stock market reacted negatively to the news, with Novo Nordisk's American depositary receipts falling 17.8% on December 20, 2024. This decline followed the company's disclosure that CagriSema achieved a weight reduction of 20.4%, missing its internal 25% target and falling short of the 22.5% benchmark investors expected based on Eli Lilly's Zepbound. Additionally, Novo Nordisk admitted to altering trial protocols by allowing participants to control their own dosages, with only 57% receiving the highest dose. In a detailed 56-page decision, Judge Robert Kirsch dismissed claims related to other alleged misstatements, including references to fixed doses and Lange's projection of 'unsurpassed' weight loss, deeming the latter merely aspirational. However, the judge did not rule on the merits of the investors' surviving fraud claims regarding tolerability concerns. The trial involved approximately 3,400 adults and aimed to demonstrate a robust pipeline following Wegovy in a highly competitive anti-obesity drug market. The article also notes that Novo Nordisk has initiated its own legal action against Eli Lilly, accusing the competitor of falsely advertising Zepbound and Mounjaro. A federal judge is set to consider a request for a preliminary injunction to halt these advertisements at an upcoming hearing on August 27.